OncoMatch/Clinical Trials/NCT04459065
Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Is NCT04459065 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies IRDye800CW-nimotuzumab for lung cancer.
Treatment: IRDye800CW-nimotuzumab — The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage I, II
Performance status
KARNOFSKY/ECOG/ZUBROD 0–2
Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2
Prior therapy
Cannot have received: anti-EGFR antibody therapy (cetuximab, panitumumab, necitumumab)
Received anti-EGFR antibody therapy (cetuximab, panitumumab, necitumumab) within 60 days prior to trial drug
Cannot have received: neoadjuvant therapy
No neoadjuvant therapy
Lab requirements
Blood counts
Hemoglobin (hgb) ≥ 90 g/L; White blood cell count (WBC) > 3 x 10^9/L; Platelet count (plt) ≥ 100 x 10^9/L
Kidney function
Serum creatinine ≤ 1.5 times upper reference range
Cardiac function
Adequate cardiopulmonary reserve to undergo lung resection as determined by operating surgeon
Adequate cardiopulmonary reserve to undergo lung resection as determined by operating surgeon; Hemoglobin (hgb) ≥ 90 g/L; White blood cell count (WBC) > 3 x 10^9/L; Platelet count (plt) ≥ 100 x 10^9/L; Serum creatinine ≤ 1.5 times upper reference range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify